BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 19333944)

  • 1. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
    Kavanaugh A; Mease P
    J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
    Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
    Kavanaugh A; McInnes IB; Mease PJ; Krueger GG; Gladman DD; van der Heijde D; Mudivarthy S; Xu W; Mack M; Xu Z; Beutler A
    Ann Rheum Dis; 2013 Nov; 72(11):1777-85. PubMed ID: 23161902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P; Fleischmann RM; Doyle MK; Strusberg I; Durez P; Nash P; Amante E; Churchill M; Park W; Pons-Estel B; Xu W; Xu S; Wu Z; Hsia EC
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
    Kavanaugh A; McInnes IB; Mease P; Krueger GG; Gladman D; van der Heijde D; Zhou Y; Lu J; Leu JH; Goldstein N; Beutler A
    Ann Rheum Dis; 2014 Sep; 73(9):1689-94. PubMed ID: 24748630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.